This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mcintyre, M. Articles by Small, M. Search for Related Content Social Bookmarking                         What's this?

The Glasgow Chart — a simple method for calculation of cardiovascular risk in type 2 diabetes

Department of Diabetes and Endocrinology, Royal Alexandra Hospital, Corsebar Road, Paisley, PA2 9PN, UK, martin.mcintyre{at}rah.scot.nhs.uk, Diabetes Centre, Gartnavel General Hospital, Glasgow, G12 0YN, UK

Stuart Kerr

Diabetes Centre, Gartnavel General Hospital, Glasgow, G12 0YN, UK

Brian Kennon

Diabetes Centre, Gartnavel General Hospital, Glasgow, G12 0YN, UK

Michael Small

Diabetes Centre, Gartnavel General Hospital, Glasgow, G12 0YN, UK

Aims Current guidelines for lipid lowering as primary prevention advocate a treatment threshold 10-year coronary heart disease (CHD) risk of 30%. There is a variety of methods of calculating CHD risk, of varying complexity, which incorporate different factors. We aimed to determine if different methods of CHD risk calculation give different results and if a simpler method of CHD risk calculation could be developed for type 2 diabetes.

Methods Using three recognised methods based on the Framingham equation, CHD risk was calculated for 200 consecutive patients with type 2 diabetes attending the clinic. A simple method of establishing those who should be treated with lipid-lowering agents was developed and sensitivity and specificity compared to the established method.

Results Using method 1, only 58 (29%) of the patients would be above the treatment threshold; 108 (54%) with method 2; and 140 (70%) with method 3 ( ²=68.3, p < 0.001). Using the Glasgow Chart, sensitivity and specificity would be 100% and 85% respectively if patients are identified with total cholesterol 5.0 mmol/L plus two of: 1) age 50 years; 2) blood pressure 140/80 mmHg; 3) microalbuminuria.

Conclusions It makes a significant difference which method is used to calculate CHD risk. Our simple method seems to be applicable to patients with type 2 diabetes, but requires confirmation in a larger population.

Key Words: Coronary heart disease • risk • diabetes • lipids.

References

• Kannel WB, McGee DL Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2(2): 120-6.[Abstract]
• Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pyorala K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.[Abstract]
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.[Abstract/Free Full Text]
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Meade T., Sleight P., Collins R. et al. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 1999;20:725-41.[Abstract/Free Full Text]
• Haffner SM, Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
• Haffner SM Is all coronary heart disease prevention in type 2 diabetes mellitus secondary prevention? J Clin Endocrinol Metab 2000;85:2108-10.[Free Full Text]
• Wood D., Durrington P., Poulter N., McInnes G., Rees A., Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-S29.[Free Full Text]
• Ramsay LE, Williams B., Johnston GD et al. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Peters TJ, Montgomery AA, Fahey T. How accurately do primary health care professionals use cardiovascular risk tables in the management of hypertension? Brit J Gen Pract 1999;49:987-8.
• Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998;16:1407-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and nondiabetic subjects. Diabet Med 1999;16:219-27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Grover SA, Coupal L., Zowall H., Alexander CM, Weiss TW, Gomes DRJ. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50.[Abstract/Free Full Text]
• Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18.[Abstract/Free Full Text]
• Arthur R. DAIS results show benefits of fenofibrate in diabetes. Brit J Cardiol 2000;7:455-6.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 3, 208-210 (2002)
DOI: 10.1177/14746514020020031201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mcintyre, M. Articles by Small, M. Search for Related Content Social Bookmarking                         What's this?